Recalibrating sham-relative superiority thresholds in BPH device trials

Sham-controlled trials of minimally invasive surgical therapies for benign prostatic hyperplasia (BPH) increasingly use early mean change in International Prostate Symptom Score (IPSS) and sham-relative "super-superiority" thresholds as primary efficacy criteria. This article examines how this framework may affect interpretation of device efficacy when sham responses are strong, while emphasizing that rigorous sham controls remain essential for distinguishing device-specific benefit from placebo, expectancy, regression to the mean, and nonspecific procedural effects.

We provide a methodological perspective on the statistical, clinical, and regulatory implications of defining superiority margins as a fixed percentage of sham improvement, with emphasis on BPH device trials using 3-month IPSS change as the primary endpoint and the need to contextualize early symptom changes against longer-term durability, retreatment, and sustained clinical benefit.

Because the required superiority margin increases as sham improvement increases, sham-relative testing can create a moving efficacy threshold. Strong sham effects should not be interpreted automatically as evidence of an unfair trial design; they may also indicate that the specific therapeutic effect of a device is smaller than initially assumed. Three-month endpoints can provide useful early signals and may facilitate efficient trial conduct, regulatory review, and commercialization; however, they are not necessarily reliable surrogates for durable therapeutic success. The statistical consequences of sham-relative testing, including scaling of the sham mean and variance, are expected features of the prespecified framework rather than evidence of methodological invalidity. The key concerns are reduced statistical efficiency, sample-size implications, clinical interpretability, and the regulatory question of how best to define clinically meaningful benefit beyond placebo and nonspecific procedural effects.

BPH device trials should continue to use rigorous sham-controlled designs when appropriate, particularly in a rapidly evolving and commercially active device landscape. At the same time, trial success should not rely disproportionately on transient early IPSS changes or efficacy thresholds that are difficult to interpret clinically. Recalibrating efficacy assessment around fixed MCID-based IPSS differences, responder-based outcomes, durability, retreatment-free survival, recovery time, and preservation of sexual function may improve interpretability without weakening the expectation that devices demonstrate benefit beyond placebo and expectancy effects.